angiotensin ii has been researched along with cerivastatin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bieringer, M; Dechend, R; Fiebeler, A; Ganten, D; Haller, H; Lindschau, C; Luft, FC; Mervaala, EM; Müller, DN; Park, JK; Schäfer, O; Schmidt, F; Schneider, W | 1 |
| Bischoff, H; Dechend, R; Dietz, R; Fiebler, A; Haller, H; Lindschau, C; Luft, FC; Müller, D; Park, JK | 1 |
| Bieringer, M; Dechend, R; Dietz, R; Fiebeler, A; Gulba, D; Haller, H; Luft, FC; Mervaala, E; Muller, DN; Park, JK; Theuer, J | 1 |
| Siegel-Axel, DI | 1 |
| Delles, C; Fleischmann, EH; John, S; Schmidt, BM; Schmieder, RE; Schneider, MP | 1 |
| Howes, JB; Howes, LG; Lowy, A; Tran, D | 1 |
2 review(s) available for angiotensin ii and cerivastatin
| Article | Year |
|---|---|
Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition.
Topics: Angiotensin II; Animals; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Pyridines | 2001 |
Cerivastatin: a cellular and molecular drug for the future?
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Arteriosclerosis; Endothelium, Vascular; Epoprostenol; Extracellular Matrix; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Monocytes; Muscle, Smooth, Vascular; Neovascularization, Physiologic; Pyridines; Receptors, Angiotensin; Thrombosis | 2003 |
2 trial(s) available for angiotensin ii and cerivastatin
| Article | Year |
|---|---|
The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men.
Topics: Adolescent; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyridines; Severity of Illness Index; Tetrazoles; Triglycerides; Vascular Resistance; Vasoconstrictor Agents | 2004 |
Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.
Topics: Acetylcholine; Aged; Analysis of Variance; Angiotensin II; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Infusions, Intravenous; Male; Middle Aged; Nitric Oxide Synthase; Nitroprusside; Norepinephrine; omega-N-Methylarginine; Pyridines; Vascular Resistance; Vasodilator Agents | 2005 |
3 other study(ies) available for angiotensin ii and cerivastatin
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Blood Pressure; Cell Division; Cholesterol; Creatinine; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Kidney; Kidney Failure, Chronic; Leukocytes; Male; Mitogen-Activated Protein Kinases; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Organ Size; Phosphorylation; Plasminogen Activators; Pyridines; Rats; Rats, Sprague-Dawley; Renin; Thromboplastin; Transcription Factor AP-1; Urea; Vascular Cell Adhesion Molecule-1; Vasoconstrictor Agents | 2000 |
Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor.
Topics: Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Blood Pressure; Cardiovascular Diseases; CD4 Antigens; CD8 Antigens; Collagen; Fibroblast Growth Factor 2; Fibronectins; Gene Expression Regulation; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-6; Male; Myocardium; NF-kappa B; Oligonucleotides; Protein Binding; Pyridines; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Survival Analysis; Survival Rate; Transcription Factor AP-1 | 2001 |